2023 World Conference on Lung Cancer (Posters)-P1.27. BRAF Mutations Identify Non-small-Cell Lung Cancer Patients Who Benefit from Neoadjuvant Chemo-Immunotherapy

P1.27. BRAF Mutations Identify Non-small-Cell Lung Cancer Patients Who Benefit from Neoadjuvant Chemo-Immunotherapy - PDF(Abstract)

Back to course

Pdf Summary

In this presentation at the World Conference on Lung Cancer 2023, the authors discuss the impact of BRAF mutations on the effectiveness of neoadjuvant chemo-immunotherapy in patients with non-small-cell lung cancer (NSCLC). Previous studies have shown that this treatment has high efficacy in locally advanced NSCLC, but little is known about the influence of tumor molecular alterations on survival outcomes.<br /><br />The authors conducted a retrospective study using samples from patients enrolled in the NADIM and NADIMII clinical trials. They analyzed plasma samples and pre-treatment biopsy samples to identify BRAF mutations using next-generation sequencing techniques. They found that 4.35% of the patients had pathogenic BRAF mutations.<br /><br />The results showed that patients with BRAF-positive tumors had a 100% pathological complete response (pCR) rate after neoadjuvant treatment, compared to a pCR rate of 44.3% in patients with BRAF-wild type tumors. Additionally, all patients with BRAF mutations were alive with no evidence of disease at the time of the study's data cutoff.<br /><br />The study also found that BRAF mutation status was not associated with clinicopathological characteristics such as sex, age, histology, ECOG, and smoking history.<br /><br />Based on these findings, the authors suggest that BRAF pathogenic variants may be a good prognostic factor in locally advanced NSCLC patients treated with neoadjuvant chemo-immunotherapy.<br /><br />Overall, this study provides valuable insights into the role of BRAF mutations in predicting treatment response and outcomes in NSCLC patients.

Asset Subtitle

Lucia Robado de Lope

Meta Tag

Speaker Lucia Robado de Lope

Topic Early-Stage NSCLC: Innovation & New Technology

Keywords

BRAF mutations

neoadjuvant chemo-immunotherapy

non-small-cell lung cancer

NSCLC

tumor molecular alterations

pathological complete response

next-generation sequencing techniques

NADIM and NADIMII clinical trials

prognostic factor

treatment response